|
Delayed
Nasdaq
02:30:00 07/01/2026 am IST
|
5-day change | 1st Jan Change | ||
| 221.38 USD | +0.03% |
|
-.--% | +0.22% |
| 09/01 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2000 Value Benchmark | CI |
| 09/01 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2500 Value Benchmark | CI |
| Market Cap | 695.9Cr 618.1Cr 578.03Cr 526.74Cr 991.66Cr 67TCr 1.01TCr 6.99TCr 2.71TCr 34TCr 2.61TCr 2.56TCr 1,09600Cr | P/E 2023 |
-3.03x | P/E 2024 | -1.01x |
|---|---|---|---|---|---|
| Enterprise Value | 677.27Cr 601.55Cr 562.56Cr 512.64Cr 965.12Cr 65TCr 978.39Cr 6.81TCr 2.63TCr 33TCr 2.54TCr 2.49TCr 1,06700Cr | EV / Sales 2023 |
0.64x | EV / Sales 2024 | 84.5x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
Last Transcript: Cidara Therapeutics
| 1 day | +0.03% | ||
| Current year | +0.22% |
| Current year | 220.47 |  | 221.42 |
| 1 year | 93 | | 221.42 |
| 3 years | 10 | | 221.42 |
| 5 years | 8 | | 221.42 |
| 10 years | 8 | | 237 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Karbe
DFI | Director of Finance/CFO | 58 | 24/02/2025 |
Corrina Pavetto
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2025 |
| Chief Tech/Sci/R&D Officer | - | 01/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 07/01/26 | Issuer sale | Chief Financial Officer | 1,65,651 | 0.6532% | ||
| 07/01/26 | Issuer sale | Director | 35,375 | 0.1395% | ||
| 07/01/26 | Issuer sale | Chief Operating Officer | 2,41,829 | 0.9537% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 6.39Cr 5.68Cr 5.31Cr 4.84Cr 9.11Cr 615.28Cr 9.23Cr 64Cr 25Cr 313.35Cr 24Cr 23Cr 1.01TCr | 12.75L 11.32L 10.59L 10L 18.17L 12Cr 18.42L 1.28Cr 49.6L 6.25Cr 47.87L 46.83L 20Cr |
| Net income | -2.29Cr -2.04Cr -1.9Cr -1.74Cr -3.27Cr -220.78Cr -3.31Cr -23Cr -8.92Cr -112.44Cr -8.61Cr -8.42Cr -361.15Cr | -17Cr -15Cr -14Cr -13Cr -24Cr -1.64TCr -25Cr -170.65Cr -66Cr -832.74Cr -64Cr -62Cr -2.67TCr |
| Net Debt | -3.09Cr -2.74Cr -2.57Cr -2.34Cr -4.4Cr -297.52Cr -4.46Cr -31Cr -12Cr -151.52Cr -12Cr -11Cr -486.67Cr | -19Cr -17Cr -15Cr -14Cr -27Cr -1.79TCr -27Cr -187.15Cr -72Cr -913.26Cr -70Cr -68Cr -2.93TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CDTX Stock
Select your edition
All financial news and data tailored to specific country editions
